Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study

Introduction Management of retroperitoneal sarcoma (RPS) remains controversial, with the mainstay of treatment being surgery. While neoadjuvant radiation demonstrated no improvement in recurrence-free survival in a prospective randomized trial (STRASS), the role of neoadjuvant chemotherapy (NCT) rem...

Full description

Saved in:
Bibliographic Details
Published inAnnals of surgical oncology Vol. 30; no. 11; pp. 6886 - 6893
Main Authors Tortorello, Gabriella N., Li, Eric H., Sharon, Cimarron E., Ma, Kevin L., Maki, Robert G., Miura, John T., Fraker, Douglas L., DeMatteo, Ronald P., Karakousis, Giorgos C.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.10.2023
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1068-9265
1534-4681
1534-4681
DOI10.1245/s10434-023-13933-2

Cover

More Information
Summary:Introduction Management of retroperitoneal sarcoma (RPS) remains controversial, with the mainstay of treatment being surgery. While neoadjuvant radiation demonstrated no improvement in recurrence-free survival in a prospective randomized trial (STRASS), the role of neoadjuvant chemotherapy (NCT) remains unknown and is the subject of ongoing study (STRASS2). Methods Patients who underwent surgical resection of high-grade RP leiomyosarcoma (LMS) or dedifferentiated liposarcoma (DDLS) were identified from the National Cancer Database (2006–2019). Predictors of NCT were analyzed using univariate and multivariate logistic regression analyses. Differences in 5-year survival were examined using the Kaplan–Meier (KM) method and by Cox proportional hazard modeling. Results A total of 2656 patients met inclusion criteria. Fifty-seven percent of patients had DDLS and 43.5% had LMS. Six percent of patients underwent NCT. Patients who received NCT were younger (median age 60 vs 64 years, p < 0.001) and more likely to have LMS (OR 1.4, p = 0.04). In comparing NCT with no-NCT patients, there was no difference in 5-year overall survival (OS) on KM analysis (57.3% vs 52.8%, p = 0.38), nor was any difference seen after propensity matching (54.9% vs 49.1%, p = 0.48, N = 144 per group). When stratified by histology, there was no difference in OS based on receipt of NCT (LMS: 59.8% for NCT group, 56.6% for no-NCT, p = 0.34; DDLS: 54.2% for NCT group, 50.1% for no-NCT, p = 0.99). Conclusion In patients undergoing surgical resection of RP LMS or DDLS, NCT does not appear to confer an OS advantage. Prospective randomized data from STRASS2 will confirm or refute these retrospective data.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1068-9265
1534-4681
1534-4681
DOI:10.1245/s10434-023-13933-2